DE602005010246D1 - Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration - Google Patents

Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration

Info

Publication number
DE602005010246D1
DE602005010246D1 DE602005010246T DE602005010246T DE602005010246D1 DE 602005010246 D1 DE602005010246 D1 DE 602005010246D1 DE 602005010246 T DE602005010246 T DE 602005010246T DE 602005010246 T DE602005010246 T DE 602005010246T DE 602005010246 D1 DE602005010246 D1 DE 602005010246D1
Authority
DE
Germany
Prior art keywords
oligopeptides
concentration
firm
increased blood
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005010246T
Other languages
English (en)
Inventor
Nisar Ahmed Khan
Robbert Benner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotempt BV
Original Assignee
Biotempt BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt BV filed Critical Biotempt BV
Publication of DE602005010246D1 publication Critical patent/DE602005010246D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
DE602005010246T 2004-04-08 2005-04-08 Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration Active DE602005010246D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/821,256 US20050227925A1 (en) 2004-04-08 2004-04-08 Compositions capable of reducing elevated blood urea concentration
PCT/EP2005/003707 WO2005097163A1 (en) 2004-04-08 2005-04-08 Oligopeptides for reducing elevated blood urea concentration

Publications (1)

Publication Number Publication Date
DE602005010246D1 true DE602005010246D1 (de) 2008-11-20

Family

ID=34963497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010246T Active DE602005010246D1 (de) 2004-04-08 2005-04-08 Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration

Country Status (21)

Country Link
US (2) US20050227925A1 (de)
EP (1) EP1755634B1 (de)
JP (1) JP4732438B2 (de)
KR (1) KR101217025B1 (de)
CN (1) CN101014356B (de)
AT (1) ATE410178T1 (de)
AU (1) AU2005230403B2 (de)
CA (1) CA2561833C (de)
CY (1) CY1108689T1 (de)
DE (1) DE602005010246D1 (de)
DK (1) DK1755634T3 (de)
ES (1) ES2315858T3 (de)
HK (1) HK1107030A1 (de)
HR (1) HRP20090003T3 (de)
IL (1) IL178515A (de)
NZ (1) NZ550574A (de)
PL (1) PL1755634T3 (de)
PT (1) PT1755634E (de)
RS (1) RS50727B (de)
SI (1) SI1755634T1 (de)
WO (1) WO2005097163A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
DE102005045152A1 (de) * 2005-09-21 2007-03-22 Stremmel, Wolfgang, Prof. Dr. Verwendung von therapeutisch wirksamen Lipiden nebst Verfahren zur Herstellung von Organ-/Gewebe-spezifischen therapeutisch wirksamen Lipiden
JP5307559B2 (ja) * 2006-03-07 2013-10-02 バイオテンプト ビー．ブイ． 放射線障害の制御の為にペプチドを使用する方法
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
SG178780A1 (en) * 2007-02-12 2012-03-29 Biotempt Bv Treatment of trauma-hemorrhage with short oligopeptides
WO2009014440A1 (en) * 2007-07-23 2009-01-29 Biotempt B.V. Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides
CN113499349B (zh) * 2021-07-13 2023-11-21 西南民族大学 一种慢性肾功能衰竭治疗用爬沙虫提取物及其制备方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5822474B2 (ja) * 1980-06-10 1983-05-09 天野製薬株式会社 コレシストキニン・パンクレオザイミンｃ端ペプチドアミドスルフエ−トエステルの製造法
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US4571336A (en) * 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4977244A (en) * 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US5002961A (en) * 1987-10-19 1991-03-26 Merrell Dow Pharmaceuticals Method for reducing injury with imidazol-2-thionecarboxamides
ATE136551T1 (de) * 1988-05-10 1996-04-15 Alpha 1 Biomedicals Inc Festphase-verfahren zur gewinnung von thymosin- alpha-1
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US6051596A (en) * 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US5223397A (en) * 1991-06-05 1993-06-29 Sangstat Medical Corporation Soluble hla cross-match
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
PT633929E (pt) * 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5380668A (en) * 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US5677275A (en) * 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US5851997A (en) * 1994-10-04 1998-12-22 Harris; Pamela Jo Use of human chorionic gonadotropin as an immune-potentiating antiviral agent
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
WO1996032412A1 (fr) * 1995-04-13 1996-10-17 Chugai Seiyaku Kabushiki Kaisha PEPTIDE SUPPRIMANT LA PHOSPHORYLATION IxB$g(a)
US5942494A (en) * 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
US6361992B1 (en) * 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
GB9624927D0 (en) * 1996-11-29 1997-01-15 Oxford Glycosciences Uk Ltd Gels and their use
US5966712A (en) * 1996-12-12 1999-10-12 Incyte Pharmaceuticals, Inc. Database and system for storing, comparing and displaying genomic information
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6583109B1 (en) * 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (de) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
IL143219A0 (en) * 1998-11-20 2002-04-21 Mount Sinai Hospital Corp Peptides that modulate the interaction of b class ephrins and pdz domains
US6507788B1 (en) * 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
WO2000053621A2 (en) * 1999-03-09 2000-09-14 Jeffrey Lynn Haddox Synthetic complementary peptides and ophthalmologic uses thereof
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
RU2157233C1 (ru) * 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU2001245537A1 (en) * 2000-03-10 2001-09-24 Monsanto Company Anti-hypertensive peptides
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6539102B1 (en) * 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
EP1217540A1 (de) * 2000-11-29 2002-06-26 Lafayette Software Inc. Methode zum Organisieren von Daten und zum Verarbeiten von Anfragen in einem Datenbanksystem, Datenbanksystem und Softwareprodukt zur Implementierung solcher Methode
WO2002095030A2 (en) * 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7135286B2 (en) * 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes

Also Published As

Publication number Publication date
WO2005097163A1 (en) 2005-10-20
AU2005230403B2 (en) 2009-05-21
HRP20090003T3 (en) 2009-02-28
CA2561833A1 (en) 2005-10-20
IL178515A0 (en) 2007-02-11
IL178515A (en) 2011-12-29
JP2007532510A (ja) 2007-11-15
CA2561833C (en) 2014-05-27
AU2005230403A1 (en) 2005-10-20
ES2315858T3 (es) 2009-04-01
JP4732438B2 (ja) 2011-07-27
KR101217025B1 (ko) 2013-01-02
PT1755634E (pt) 2009-01-15
KR20070036029A (ko) 2007-04-02
DK1755634T3 (da) 2009-02-16
ATE410178T1 (de) 2008-10-15
CY1108689T1 (el) 2014-04-09
NZ550574A (en) 2008-08-29
EP1755634B1 (de) 2008-10-08
US20050227925A1 (en) 2005-10-13
RS50727B (sr) 2010-08-31
CN101014356A (zh) 2007-08-08
SI1755634T1 (sl) 2009-04-30
EP1755634A1 (de) 2007-02-28
HK1107030A1 (en) 2008-03-28
PL1755634T3 (pl) 2009-03-31
US20060142205A1 (en) 2006-06-29
CN101014356B (zh) 2012-06-13

Similar Documents

Publication Publication Date Title
DE602005010246D1 (de) Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration
NO2017027I1 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
EP1855719A4 (de) Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
DE502005006284D1 (de) Keratin-bindende polypeptide
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
PE20090711A1 (es) Region constante de anticuerpo mutante
CY1111411T1 (el) Αναλογα του παρομοιου-με-την-γλυκαγονη-πεπτιδιου-2(glp-2)
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
GEP20135981B (en) Erythropoietin receptor peptide formulations and usage thereof
WO2007047969A3 (en) Methods of decreasing vascular calcification using il-1 inhibitors
BRPI0314666B8 (pt) composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
WO2008063865A3 (en) Biphosphonate inhalant formulations and methods for using the same
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases
GB0620255D0 (en) Antibody and uses thereof
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
ATE451112T1 (de) Oligopeptide enthaltende dermatologische zusammensetzungen zur steigerung der hautempfindlichkeit
TR200400639T4 (tr) Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
SE0300586D0 (sv) Diagnosis of autism
WO2006029343A3 (en) Peptides that selectively home to heart vasculature and related conjugates and methods
EP1801232A4 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
RU2010136820A (ru) Новый белок fer-типа, содержащая его фармацевтическая композиция и способ его использования

Legal Events

Date Code Title Description
8364 No opposition during term of opposition